Active Commuting To Improve Well-being and Health in Everyday Life

Conditions

Overweight and Obesity

Brief summary

The aim of present randomized controlled trial is to evaluate the health effects of physical activity in transport and leisure time domains of everyday life and to develop durable physical activity regimens, i.e. to go from lifestyle intervention to daily lifestyle routine, in overweight individuals. Subjects will be randomized to 1 of 4 groups. 1: Vigorous intensity leisure time physical activity, 2: Moderate intensity leisure time activity, 3: Active commuting by bicycle, or 4: a non-intervention control group

Jonas Salling Quist, Mads Rosenkilde, Anne Sofie Gram, Martin Bæk Blond, Daniel Holm-Petersen et al. (8 authors)

Journal of Obesity2019-04-0717 citations

10.1155/2019/2189034

How does 6 months of active bike commuting or leisure-time exercise affect insulin sensitivity, cardiorespiratory fitness and intra-abdominal fat? A randomised controlled trial in individuals with overweight and obesity

Martin Bæk Blond, Mads Rosenkilde, Anne Sofie Gram, Marie Tindborg, Anders Nymark Christensen et al. (7 authors)

British Journal of Sports Medicine2019-03-1641 citations

10.1136/bjsports-2018-100036

Effects of active commuting and leisure-time exercise on fat loss in women and men with overweight and obesity: a randomized controlled trial.

Quist JS, Rosenkilde M, Petersen MB, Gram AS, Sjödin A, Stallknecht B.

2017-10-1036 citations

10.1038/ijo.2017.253

Interventions

BEHAVIORALPhysical activity

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy * No engagement in habitual structured physical activity * Body mass index 25-35 kg/m2 * Body fat percentage \>32% for women and \>25% for men * Maximum oxygen uptake (VO2max) \<40 ml O2/kg/min for women and \<45 ml O2/kg/min for men * Ethnicity: Caucasian

Exclusion criteria

* Chronic use of medicine * Smoking * Fasting plasma glucose \> 6,1 mmol/L * Blood pressure \> 140/90 mm Hg * Abnormal resting and working ECG * Parents or siblings with diagnosed type 2 diabetes * For women: Follicle stimulating hormone (FSH) concentration \> 35 milliunits/ml, pregnancy or planning of pregnancy within the coming year

Design outcomes

Primary

Measure	Time frame	Description
Haemostatic balance	Change from baseline in endogenous thrombin potential at 3 months	Blood coagulation measured by fasting levels of endogenous thrombin potential (nM x min)
Peripheral insulin sensitivity (glucose clearance ml/min/kg fat-free mass/nM insulin)	Change from baseline in peripheral insulin sensitivity at 3 months	Measured using the hyper-insulinemic euglycaemic clamp

Secondary

Measure	Time frame	Description
Central insulin sensitivity	Baseline, 3 and 6 months	Fasting plasma insulin, homeostasis model assessment insulin resistance and measures of central insulin sensitivity derived from an oral glucose tolerance test
Maximal oxygen uptake (ml/O2/kg/min)	Baseline, 3 and 6 months	Measured using indirect calorimetry and an incremental bicycle protocol
Abdominal fat mass	Baseline, 3 and 6 months	Visceral intrabdominal and subcutaneous fat mass determined by magnetic resonance imaging
Metabolic syndrome	Baseline, 3 and 6 months	As measured by high density lipoprotein, triglycerides, waist circumference, blood pressure, mean arterial pressure, fasting glucose and composite metabolic syndrome scores
Haemostatic balance II	Baseline, 3 and 6 months	1: Coagulation: Fibrinogen, Tissue factor(TF), prothrombin fragment 1+2. 2: Fibrinolysis: Tissue type plasminogen activator(tPA:AG), Plasminogen activator inhibitor type 1(PAI-1:AG). 3: Endothelial cell function: von Willebrand factor(vWF), Tissue factor pathway inhibitor (TFPI). 4: Inflammation: C-Reactive protein.
Anthropometry	Baseline, 3 and 6 months	Measured using dual x-ray absorptiometry, height, weight, waist and hip circumference, sagittal abdominal height
Sleep habits	Baseline, 3 and 6 months	Sleep duration and quality measured using accelerometers, logs and questionaires (Pittsburgh sleep quality index and Epworth sleepiness scale)
Skeletal muscle biopsy	Baseline, 3 and 6 months	Biochemical, proteomics, metabolomics, genomics and morphological analyses
Subcutaneous adipose tissue biopsy	Baseline, 3 and 6 months	Biochemical, proteomics, metabolomics, genomics and morphological analyses
Health related quality of life and other psycho-social outcomes	Baseline, 3 and 6 months	Measured using questionaries (SF-36), semi-structured interviews and observations
Glycaemic control	Baseline, 3 and 6 months	Fasting plasma glucose, 1- and 2-hour plasma glucose and glucose area under the curve measured during an oral glucose tolerance test

Other

Measure	Time frame	Description
Exercise compliance	Baseline, 3 and 6 month	Adherence to the exercise protocol as measured using heart rate and global positioning system monitors will be assessed and individually adjusted continuously over the course of the exercise intervention

Countries

Denmark

Outcome results

None listed